Antibodies to high mobility group proteins in systemic sclerosis - PubMed (original) (raw)
. 1994 Nov;21(11):2071-5.
Affiliations
- PMID: 7869312
Antibodies to high mobility group proteins in systemic sclerosis
L M Ayer et al. J Rheumatol. 1994 Nov.
Abstract
Objective: To determine the prevalence of autoantibodies to high mobility group (HMG) proteins in systemic sclerosis (SSc).
Methods: One hundred ninety-seven unselected sera from patients diagnosed as SSc (n = 180) or Raynaud's phenomenon (RP) (n = 17) were tested for HMG autoantibodies by ELISA and immunoblotting.
Results: Seventy-one of the 180 (39.0%) SSc sera bound to HMG proteins in an ELISA: 56 (31%) to HMG-1 and/or HMG-2; 29 (16%) to HMG-14/17. In the same assay, 7 of 17 RP sera (41%) bound to HMG proteins: 4 (23%) to HMG-1 and/or HMG-2, and 5 (29%) to HMG-14/17. The specificity of HMG binding was confirmed by immunoblotting.
Conclusion: Antibodies to HMG proteins, particularly to HMG-1 and HMG-2 are found in about 1/3 of SSc Sera. Since HMG-1 and HMG-2 have a role in transcription, these observations further implicate transcriptional complexes as targets of autoantibodies in scleroderma. This is the first published report of HMG autoantibodies in scleroderma.
Similar articles
- Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
Vázquez-Abad D, Grodzicky T, Senécal JL. Vázquez-Abad D, et al. Clin Immunol. 1999 Feb;90(2):182-9. doi: 10.1006/clim.1998.4643. Clin Immunol. 1999. PMID: 10080829 - Autoantibodies to HMG-17 nucleosomal protein in patients with scleroderma.
Vlachoyiannopoulos PG, Boumba VA, Tzioufas AG, Seferiadis C, Tsolas O, Moutsopoulos HM. Vlachoyiannopoulos PG, et al. J Autoimmun. 1994 Apr;7(2):193-201. doi: 10.1006/jaut.1994.1015. J Autoimmun. 1994. PMID: 8037838 - Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
Shoenfeld Y, Grunebaum E, Laufer M, Zurgil N, Bakimer R, Lunderschmidt A, Valentini G, Tirri G, Blank M. Shoenfeld Y, et al. Isr J Med Sci. 1996 Jul;32(7):537-42. Isr J Med Sci. 1996. PMID: 8756980 Review. - Diagnostic criteria of systemic sclerosis.
Hudson M, Fritzler MJ. Hudson M, et al. J Autoimmun. 2014 Feb-Mar;48-49:38-41. doi: 10.1016/j.jaut.2013.11.004. Epub 2014 Jan 22. J Autoimmun. 2014. PMID: 24461384 Review.
Cited by
- High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.
Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. Andersson U, et al. J Exp Med. 2000 Aug 21;192(4):565-70. doi: 10.1084/jem.192.4.565. J Exp Med. 2000. PMID: 10952726 Free PMC article. - Emerging role of HMGB1 in fibrotic diseases.
Li LC, Gao J, Li J. Li LC, et al. J Cell Mol Med. 2014 Dec;18(12):2331-9. doi: 10.1111/jcmm.12419. Epub 2014 Oct 6. J Cell Mol Med. 2014. PMID: 25284457 Free PMC article. Review. - Coherent somatic mutation in autoimmune disease.
Ross KA. Ross KA. PLoS One. 2014 Jul 2;9(7):e101093. doi: 10.1371/journal.pone.0101093. eCollection 2014. PLoS One. 2014. PMID: 24988487 Free PMC article. Review. - Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.
Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C. Qing X, et al. Immunol Lett. 2008 Nov 16;121(1):61-73. doi: 10.1016/j.imlet.2008.08.007. Epub 2008 Sep 24. Immunol Lett. 2008. PMID: 18822317 Free PMC article. - Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.
Liu J, Zhao J, Hu L, Cao Y, Huang B. Liu J, et al. Cell Mol Immunol. 2011 Jul;8(4):289-95. doi: 10.1038/cmi.2011.6. Epub 2011 Mar 21. Cell Mol Immunol. 2011. PMID: 21423201 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous